Filing Flows › Elite Pharmaceuticals (ELTP) › Q1 FY26
Elite Pharmaceuticals (ELTP) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Aug 14, 2025
Elite Pharmaceuticals (ELTP) reported revenue of $40.2M for the first quarter fiscal 2026 (Q1 FY26), +114% from a year earlier and +26% from the quarter before. Operating margin was 54.0%, net loss $5.9M (14.6% of revenue).
Elite Pharmaceuticals, Q1 FY26: revenue $40.2M (+114% year over year), operating margin 54.0%, net loss $5.9M, operating cash flow $14.8M. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $40.2M | +26% | +114% |
| Operating profit | $21.7M | +95% | — |
| Net earnings | −$5.9M | -135% | — |
| Operating cash flow | $14.8M | +277% | +370% |
| Free cash flow | $14.6M | +360% | +515% |
What changed
Revenue was $40.2M in Q1 FY26, up 114% year over year and up 26% from the previous quarter. Manufacturing was the largest line at 99% of revenue. Manufacturing added $21.3M year over year (up 116%), 100% of the total change.
Gross margin was 67.7%, up 22.6 points from a year earlier. Operating profit was $21.7M, a 54.0% margin (up 33.4 points year over year). Of the extra revenue versus a year earlier, 83% reached operating profit, above the 21% margin then. Operating expenses grew 20% against revenue growth of 114%. The fastest-growing cost line was General & admin (+73%). The quarter ended with a net loss of $5.9M, after a profit of $17.0M the previous quarter. Net interest and other expense of $22.3M was the main reason.
Operating cash flow was $14.8M (up 370% year over year). Non-cash charges added back $275K of depreciation and $52K of share-based compensation. Working capital and other items added $20.3M. Capital expenditures of $218K left free cash flow of $14.6M.
Questions
What was Elite Pharmaceuticals' revenue in the first quarter fiscal 2026?
Elite Pharmaceuticals (ELTP) reported revenue of $40.2M for the first quarter fiscal 2026 (Q1 FY26), +114% from a year earlier and +26% from the quarter before.
Was Elite Pharmaceuticals profitable in the first quarter fiscal 2026?
Operating profit was $21.7M (54.0% of revenue) and net loss $5.9M.